Guide

Biosimilars pipeline report: A guide for understanding the growing market

To date, there have been 76 approvals and 60 launches in the U.S. biosimilars market. 

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.
Available in English only
We keep this report up to date as the biosimilars market evolves. Enter your information below to receive the newest versions to your inbox as they're released.
Pardot Form

We are Cencora. Our shared identity unites us.

Cencora brings the companies and services of AmerisourceBergen together under one new name.
Manufacturer of biosimilars

Learn more about our biosimilar solutions

We believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.

Related resources

White paper

Evolving landscape of payer coverage for cell and gene therapies (CGTs): Trends and insights

Webinar

Regulatory Data Initiatives in the EU – What you need to know for 2026

Webinar

Harnessing AI to revolutionize pharmacovigilance signal management

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.